【正大天晴是哪个国家的品牌？】

英文翻译：Zhengda Tianqing Pharmaceutical Group Co., Ltd., founded in 1997, is a high-tech enterprise, a large domestic R & D and production base of liver health drugs, a large pharmaceutical enterprise integrating scientific research, production and sales. Zhengda Tianqing Pharmaceutical Group is an innovative pharmaceutical group enterprise integrating scientific research, production and sales, and a domestic R & D and production base of liver health drugs. Zhengda Tianqing has always regarded scientific and technological innovation as an important strategy for the development of enterprises, and is one of the pharmaceutical enterprises with more investment in innovative drug research in China. With the development of enterprises and the improvement of R & D capabilities, the R & D investment of Zhengda Tianqing has exceeded 1 billion yuan / year, and will gradually match with that of multinational companies. At present, there are 247 research projects in the Research Institute, including 31 first-class new drugs and 32 biological drugs. Zhengda Tianqing has three production bases in Lianyungang, covering an area of more than 800 mu, including 160 Mu incubation base, more than 200 mu API base and 480 Mu preparation base. Zhengda Tianqing preparation base is designed and constructed in accordance with EU and US FDA standards. Small volume injection has obtained the first GMP certificate in China, and oral solid preparation has obtained the first GMP certificate in Jiangsu Province. In June 2014, the preparation base passed the EU certification and obtained the EU recognized GMP certification issued by the German Drug Administration. At present, Zhengda Tianqing is preparing for the four major products to enter the international market. In the future, these drugs will become a new weapon for Zhengda Tianqing to open the international market. Zhengda Tianqing's product treatment field involves various disease fields such as liver disease, tumor, respiration, infection, digestion and so on. 14 products with annual sales of more than 100 million yuan have formed a "hundred million yuan product group", including 2 products with annual sales of more than 2 billion yuan, which are the national first-class new drug magnesium isoglycate injection solution (Tianqing Ganmei) and the earlier listed entecavir dispersible tablet (Runzhong). In addition to the strong liver disease field, the anti-tumor field has also formed a unique product line. The blood tumor products sitabin, imatinib and dasatinib are the first imitations in China; the solid tumor products capecitabine have been approved for listing. Respiratory, antibiotic, endocrine and other fields will also be the future development direction of the enterprise. In the future, Zhengda Tianqing Pharmaceutical Co., Ltd. will continue to strengthen the building of core competitiveness, establish a sound scientific research and development system, and keep the company's research and development level in line with the international forefront.

本文链接： https://www.waitui.com/brand/31672152f.html 联系电话：800-828-5598,0518-85804002